CJC-1295 Without DAC 10mg research peptide (Mod GRF 1-29) is a 29-amino acid GHRH analogue with four DPP-IV-resistant substitutions, studied for pulsatile GH pathway stimulation via GHRHR in UK laboratories. ≥98% purity. Janoshik tested. Same-day UK dispatch. Research use only.
Form: Lyophilized peptide powder
Safety Information: Not intended for human or veterinary use. Use appropriate laboratory safety procedures when handling.
CJC-1295 WITHOUT DAC 10mg should only be used in laboratory settings by qualified personnel.
Ensure all experimental procedures comply with local and institutional regulations.
This peptide is supplied for research and scientific study purposes only.
CJC-1295 (Without DAC) 10 mg:
Click Here To View
Research use only • UK dispatch • Orders before 4pm ship same day • Secure checkout
CJC-1295 Without DAC 10mg Research Peptide UK
CJC-1295 Without DAC 10mg, also referred to as Mod GRF 1-29, is a synthetic 29-amino acid analogue of Growth Hormone Releasing Hormone (GHRH). It incorporates four amino acid substitutions that provide enhanced resistance to DPP-IV enzymatic degradation compared to both native GHRH and Sermorelin 2mg. With a molecular weight of approximately 3,367 Da, the cjc 1295 without dac research peptide acts as a selective agonist at the GHRH receptor (GHRHR) on anterior pituitary somatotroph cells.
Upon GHRHR binding, CJC-1295 without DAC 10mg initiates the cAMP and PKA signalling cascade, leading to the most widely studied GHRH analogue in combined GHRH and GHRP research protocols. Its four amino acid substitutions extend the in vitro activity window to approximately 30 minutes, longer than unmodified Sermorelin 2mg at approximately 12 minutes, but shorter than the DAC-modified version. This pulsatile activity profile is the defining research characteristic that makes it the most widely studied GHRH analogue in combined GHRH and GHRP research protocols.
CJC-1295 Without DAC 10mg is most commonly studied alongside Ipamorelin 5mg or Ipamorelin 10mg. These two compounds target mechanistically distinct receptors: CJC-1295 without DAC targets GHRHR, while ipamorelin targets GHS-R1a (the ghrelin receptor). This receptor-level distinction allows them to function as independent variables in the same experimental protocol, producing synergistic GH pathway stimulation in published research models.
For researchers comparing GHRH analogue structures, this compound can be studied alongside CJC-1295 with DAC 10mg (extended-release DAC modification), Sermorelin 2mg (native sequence, shortest half-life), and Tesamorelin 5mg (full 44-amino acid GHRH sequence). Full mechanism and combined protocol data are available in the CJC-1295 Without DAC research guide on the Ascend Peptides UK blog.
All CJC-1295 Without DAC 10mg batches are independently tested by Janoshik. HPLC purity is confirmed at greater than or equal to 98%, with LC-MS molecular identity confirmed. The full Certificate of Analysis is available for independent verification.
Reconstitute with BP-grade bacteriostatic water for research. Gently swirl. Aliquot immediately. Store at 20 °C.
WADA Status: Prohibited at all times under WADA and UKAD regulations.
DISCLAIMER: For in-vitro laboratory research only. Not for human consumption. Not an MHRA-licensed medicine.
A curated entry point for buyers comparing quality, documentation, and availability.
UK same-day dispatch – PCI-
compliant payments –
Laboratory research only
© 2026 by Ascend Peptides Uk.
